{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:05:59Z","timestamp":1753877159228,"version":"3.41.2"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients\u2019 self-report of their symptoms can provide important data for the evaluation of treatment benefit and tolerability of oncology drugs. Contemporary treatment approaches, including immunotherapy and molecular targeted therapies, have unique toxicities based on their novel mechanisms of action. This scoping review aimed to summarize evidence from existing reviews and clinical practice guidelines to examine the type and prevalence of toxicities including symptomatic adverse events (sympAEs) for adult cancer patients to inform clinical care and therapeutic trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic search of PubMed, Web of Science, and Embase was performed using predefined eligibility criteria. Thirty-one literature reviews and 3 clinical practice guidelines met inclusion criteria and were selected for review and data abstraction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Findings from this scoping review demonstrated several leading sympAEs that were reported across immunotherapy and targeted therapy drugs, including fatigue, diarrhea, and rash. In addition to these more prevalent sympAEs, there were some less frequently reported class-specific sympAEs, which had potential for significant harm or disability to the patient if not properly identified and treated. Many studies reported toxicities as AEs or syndromes solely using data reported by clinicians without additional self-report from patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We identified several core sympAEs experienced by patients participating in oncology trials using immunotherapy and targeted therapy agents, which has implications for future trial design and drug labeling. Future cancer trials should assess patient-reported sympAEs based on the identified drug mechanism to inform the tolerability of these newer agents and enhance patient safety during trial participation and clinical care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf036","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:51:38Z","timestamp":1743393098000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-6914","authenticated-orcid":false,"given":"Amanda L","family":"King","sequence":"first","affiliation":[{"name":"Office of Patient-Centered Outcomes Research, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8593-0622","authenticated-orcid":false,"given":"Tamara","family":"Vasilj","sequence":"additional","affiliation":[{"name":"Immune Deficiency Cellular Therapy Program, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Cooper","sequence":"additional","affiliation":[{"name":"National Institutes of Health Library, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-7705","authenticated-orcid":false,"given":"Elizabeth","family":"Vera","sequence":"additional","affiliation":[{"name":"Office of Patient-Centered Outcomes Research, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sefanit","family":"Berhanu","sequence":"additional","affiliation":[{"name":"Office of Patient-Centered Outcomes Research, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8084-5840","authenticated-orcid":false,"given":"Morgan","family":"Johnson","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara","family":"Locke","sequence":"additional","affiliation":[{"name":"Office of Patient-Centered Outcomes Research, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4243-771X","authenticated-orcid":false,"given":"Bennett","family":"Mciver","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-9318","authenticated-orcid":false,"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[{"name":"Division of Oncology, University of North Carolina\u2014Chapel Hill , Chapel Hill, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Statistical Research and Data Science Center, Pfizer Inc , Groton, CT,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-1085","authenticated-orcid":false,"given":"Amylou","family":"Dueck","sequence":"additional","affiliation":[{"name":"Division of Health Sciences Research, Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-9722","authenticated-orcid":false,"given":"Mark R","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-5374","authenticated-orcid":false,"given":"Lee","family":"Jones","sequence":"additional","affiliation":[{"name":"Patient Advocate ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6571-3587","authenticated-orcid":false,"given":"Yuelin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-4079","authenticated-orcid":false,"given":"Lori M","family":"Minasian","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-8714","authenticated-orcid":false,"given":"Bryce B","family":"Reeve","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine , Durham, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-0492","authenticated-orcid":false,"given":"Terri S","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Office of Patient-Centered Outcomes Research, National Cancer Institute , Bethesda, MD,","place":["United States"]},{"name":"Neuro-Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-5233","authenticated-orcid":false,"given":"Tito","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Office of Patient-Centered Outcomes Research, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"year":"2011","author":"US Food & Drug Administration","key":"2025061510471974800_pkaf036-B1"},{"author":"National Cancer Institute","key":"2025061510471974800_pkaf036-B2"},{"key":"2025061510471974800_pkaf036-B3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"New Engl J Med"},{"key":"2025061510471974800_pkaf036-B4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"key":"2025061510471974800_pkaf036-B5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/PROM.S256567","article-title":"Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE to provide two distinct and complementary perspectives","volume":"13","author":"Minasian","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"2025061510471974800_pkaf036-B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2025061510471974800_pkaf036-B7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring versus routine surveillance following treatment for lung cacer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"key":"2025061510471974800_pkaf036-B8","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025061510471974800_pkaf036-B9","first-page":"1051","article-title":"Validity and reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA"},{"key":"2025061510471974800_pkaf036-B10","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jnci\/djaa016","article-title":"Validity and reliability of the pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events","volume":"112","author":"Reeve","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2025061510471974800_pkaf036-B11","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.3390\/ijms241713618","article-title":"Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs","volume":"24","author":"Choi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025061510471974800_pkaf036-B12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.21037\/atm.2019.05.58","article-title":"Immunotherapy and targeted therapy\u2014the new roadmap in cancer treatment","volume":"7","author":"Shahid","year":"2019","journal-title":"Ann Transl Med"},{"key":"2025061510471974800_pkaf036-B13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence-based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"year":"2023","author":"Veritas Health Innovation","key":"2025061510471974800_pkaf036-B14"},{"key":"2025061510471974800_pkaf036-B15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Trans Oncol"},{"key":"2025061510471974800_pkaf036-B16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025061510471974800_pkaf036-B17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025061510471974800_pkaf036-B18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2022.58.6.3378055","article-title":"Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma","volume":"58","author":"Deshpande","year":"2022","journal-title":"Drugs Today"},{"key":"2025061510471974800_pkaf036-B19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025061510471974800_pkaf036-B20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.seminoncol.2018.09.001","article-title":"Management of immunotherapy toxicities in older adults","volume":"45","author":"Bhandari","year":"2018","journal-title":"Semin Oncol"},{"key":"2025061510471974800_pkaf036-B21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1159\/000509941","article-title":"Immune checkpoint inhibitor-related pneumonitis","volume":"99","author":"Gomatou","year":"2020","journal-title":"Respiration"},{"key":"2025061510471974800_pkaf036-B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1188\/17.CJON.S2.45-52","article-title":"Checkpoint inhibitors: common immune-related adverse events and their management","volume":"21","author":"Gordon","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"2025061510471974800_pkaf036-B23","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2025061510471974800_pkaf036-B24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jgo.2016.05.007","article-title":"The development of immunotherapy in older adults: new treatments, new toxicities?","volume":"7","author":"Helissey","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"2025061510471974800_pkaf036-B25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euf.2017.11.008","article-title":"Immunotherapy in the elderly","volume":"3","author":"Lalani","year":"2017","journal-title":"Eur Urology Focus"},{"key":"2025061510471974800_pkaf036-B26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025061510471974800_pkaf036-B27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney complications of immune checkpoint inhibitors: a review","volume":"74","author":"Shingarev","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025061510471974800_pkaf036-B28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","article-title":"Efficacy of adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer","volume":"36","author":"van Holstein","year":"2019","journal-title":"Drugs Aging"},{"issue":"suppl 13","key":"2025061510471974800_pkaf036-B29","doi-asserted-by":"crossref","first-page":"S1474","DOI":"10.21037\/jtd.2018.05.90","article-title":"Lung cancer, elderly and immune checkpoint inhibitors","volume":"10","author":"Casaluce","year":"2018","journal-title":"J Thorac Dis."},{"key":"2025061510471974800_pkaf036-B30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminoncol.2018.06.003","article-title":"Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1\/PD-L1 therapy","volume":"45","author":"King-Kallimanis","year":"2018","journal-title":"Semin Oncol"},{"key":"2025061510471974800_pkaf036-B31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2021.11.024","article-title":"Immunotherapy in older patients with hepatocellular carcinoma","volume":"162","author":"Lyu","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025061510471974800_pkaf036-B32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-022-02044-1","article-title":"New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma","volume":"39","author":"Villani","year":"2022","journal-title":"Adv Ther"},{"key":"2025061510471974800_pkaf036-B33","doi-asserted-by":"crossref","first-page":"e1019-31","DOI":"10.1016\/j.clml.2022.07.017","article-title":"Treatment landscape of relapsed\/refractory mantle cell lymphoma: an updated review","volume":"22","author":"Al-Mansour","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025061510471974800_pkaf036-B34","first-page":"42","article-title":"Adult survivorship: considerations following CAR T-cell therapy","volume":"23","author":"Buitrago","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2025061510471974800_pkaf036-B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"2025061510471974800_pkaf036-B36","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart","volume":"74","author":"Ganatra","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025061510471974800_pkaf036-B37","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1097\/CCM.0000000000003258","article-title":"Management of the critically ill adult chimeric antigen receptor-T cell therapy patient: a critical care perspective","volume":"46","author":"Gutierrez","year":"2018","journal-title":"Crit Care Med"},{"key":"2025061510471974800_pkaf036-B38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"2025061510471974800_pkaf036-B39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-016-0519-8","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults","volume":"18","author":"Ronson","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"2025061510471974800_pkaf036-B40","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1080\/10428194.2021.1964022","article-title":"Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults","volume":"62","author":"Kimble","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2025061510471974800_pkaf036-B41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T-cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"2025061510471974800_pkaf036-B42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/107327481502204s04","article-title":"Management of chronic lymphocytic leukemia in the elderly","volume":"22","author":"Barrientos","year":"2015","journal-title":"Cancer Control"},{"key":"2025061510471974800_pkaf036-B43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","article-title":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty, and organ dysfunction","volume":"137","author":"Fraz","year":"2019","journal-title":"Crit Rev Oncol"},{"key":"2025061510471974800_pkaf036-B44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40266-020-00765-y","article-title":"Management of older adults with mantle cell lymphoma","volume":"37","author":"Romancik","year":"2020","journal-title":"Drugs Aging"},{"author":"Cleveland Clinic","key":"2025061510471974800_pkaf036-B45"},{"author":"Penn Medicine","key":"2025061510471974800_pkaf036-B46"},{"key":"2025061510471974800_pkaf036-B47","doi-asserted-by":"crossref","first-page":"1272523","DOI":"10.3389\/fphar.2023.1272523","article-title":"Novel small molecules in targeted cancer therapy","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025061510471974800_pkaf036-B48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2018.11.009","article-title":"Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review","volume":"133","author":"Belgioia","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025061510471974800_pkaf036-B49","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1002\/cnr2.1590","article-title":"Mantle cell lymphoma: a clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data","volume":"5","author":"Radhakrishnan","year":"2022","journal-title":"Cancer Rep"},{"key":"2025061510471974800_pkaf036-B50","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14656566.2018.1480722","article-title":"Tivozanib for the treatment of renal cell carcinoma","volume":"19","author":"Santoni","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2025061510471974800_pkaf036-B51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/JCO.2019.37.8_suppl.97","article-title":"Emotional and cognitive disturbances in longterm melanoma survivors treated with ipilimumab","volume":"37","author":"Rogiers","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025061510471974800_pkaf036-B52","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab for the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"author":"Cancer Research UK","key":"2025061510471974800_pkaf036-B53"},{"key":"2025061510471974800_pkaf036-B54","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40266-015-0304-7","article-title":"Novel therapies for metastatic melanoma: an update on their use in older patients","volume":"32","author":"Rogiers","year":"2015","journal-title":"Drugs Aging"},{"key":"2025061510471974800_pkaf036-B55","doi-asserted-by":"crossref","first-page":"12815","DOI":"10.1038\/s41598-023-39046-0","article-title":"Prevalence of cancer-related fatigue based on severity: a systematic review and meta-analysis","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"key":"2025061510471974800_pkaf036-B56","doi-asserted-by":"crossref","first-page":"112916","DOI":"10.1016\/j.ejca.2023.05.005","article-title":"Early phase clinical trials in oncology: realising the potential of seamless designs","volume":"189","author":"Jaki","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025061510471974800_pkaf036-B57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.27219","article-title":"Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1\/2 study","volume":"99","author":"Gavriatopoulou","year":"2024","journal-title":"Am J Hematol"},{"key":"2025061510471974800_pkaf036-B58","first-page":"67","article-title":"Patient-reported outcomes in cancer clinical trials: Measuring symptomatic adverse events with the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol"},{"key":"2025061510471974800_pkaf036-B59","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","article-title":"Comparison between patient-reported and clinician-observed symptoms in oncology","volume":"36","author":"Xiao","year":"2013","journal-title":"Cancer Nurs"},{"year":"2009","author":"Food and Drug Administration","key":"2025061510471974800_pkaf036-B60"},{"year":"2021","author":"Food and Drug Administration","key":"2025061510471974800_pkaf036-B61"},{"key":"2025061510471974800_pkaf036-B62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/dju129","article-title":"Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials","volume":"106","author":"Reeve","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025061510471974800_pkaf036-B63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf036\/62786187\/pkaf036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/3\/pkaf036\/62786187\/pkaf036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/3\/pkaf036\/62786187\/pkaf036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T14:47:29Z","timestamp":1749998849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf036\/8098057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf036","relation":{},"ISSN":["2515-5091"],"issn-type":[{"type":"electronic","value":"2515-5091"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"pkaf036"}}